

## **GS-Nitroxide (JP4-039)/F15 Liposome Oral Radioprotective Therapy for FA Patients Requiring Chemoradiotherapy for HNSCC**

The Board of Directors of the Fanconi Anemia Research Fund recently approved a small grant of \$33,044 for a research proposal titled, “GS-Nitroxide (JP4-039)/F15 Liposome Oral Radioprotective Therapy for FA Patients Requiring Chemoradiotherapy for HNSCC.” This project, led by Joel Greenberger, MD, a radiation oncologist at The University of Pittsburgh Cancer Institute, will test whether this promising drug (JP4-039) delivered topically will offer radiation protection without mitigating the cancer-killing properties of radiation in a FA mouse model. Given that there may never be enough FA patients with head and neck cancer suitable for a large, traditional trial of radiation-protection drugs that might attract a large drug company to study this problem, starting with mice to generate pre-clinical data is key.

The board felt that this work has the potential for high payoff; i.e., if successful, the timeline could be relatively short to a clinical therapy for FA or other patients with head and neck cancer.